RxDoctor Payments Data

Jessica Reynolds, MD

Internal Medicine · Spartanburg, SCNPI 1861786345

Payments from drug & device makers

$621in general payments, 2019–2025

Across 38 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$228
  • Pfizer$95
  • Amgen$73
  • Dexcom, Inc.$66
  • Novartis$60
  • Astellas Pharma US Inc$30
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$620100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$621 in reported general payments places this provider in the 60th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$110,950
Medicare patients
227
Services billed
1,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide198$266,943
JardianceEmpagliflozin186$213,792
OzempicSemaglutide151$205,569
EliquisApixaban111$124,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$64,335
JanuviaSitagliptin Phosphate63$61,866
RybelsusSemaglutide31$55,358
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog46$45,430
FarxigaDapagliflozin Propanediol34$38,905
LinzessLinaclotide29$38,789
XareltoRivaroxaban32$36,007
MyrbetriqMirabegron32$34,188
Repatha SureclickEvolocumab31$30,192
TrulicityDulaglutide12$27,405
Breo ElliptaFluticasone/Vilanterol38$25,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$260,926182 claims
PfizerEliquis$95$124,178111 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$13$98,116103 claims
AbbVieLinzess$228$38,78929 claims
Astellas Pharma US IncMyrbetriq$30$34,18832 claims
NovartisEntresto$60$24,46117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →